KEYMED BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.5 HKD | -4.01% |
|
+14.92% | -31.77% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,864 | 12,600 | 12,348 | 8,936 | - | - |
| Enterprise Value (EV) 1 | 4,378 | 12,118 | 12,348 | 7,904 | 7,990 | 8,936 |
| P/E ratio | -1.16 x | -38.2 x | -32.6 x | -11 x | -12.8 x | -19.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 71.3 x | 126 x | 34.9 x | 78 x | 15.6 x | 7.24 x |
| EV / Revenue | 39.7 x | 121 x | 34.9 x | 69 x | 13.9 x | 7.24 x |
| EV / EBITDA | -10.9 x | -44.5 x | -43 x | -10.4 x | -11.7 x | -17.7 x |
| EV / FCF | -11.3 x | -17.8 x | - | -8.06 x | -9.61 x | -13.6 x |
| FCF Yield | -8.83% | -5.62% | - | -12.4% | -10.4% | -7.35% |
| Price to Book | 2.15 x | 3.74 x | - | 4.02 x | 6.07 x | 8.63 x |
| Nbr of stocks (in thousands) | 2,79,736 | 2,79,736 | 2,76,696 | 2,76,604 | - | - |
| Reference price 2 | 28.11 | 45.04 | 44.63 | 32.31 | 32.31 | 32.31 |
| Announcement Date | 29/03/22 | 17/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 110.3 | 100.1 | 354.1 | 114.6 | 573.2 | 1,234 |
| EBITDA 1 | - | -402.3 | -272.6 | -286.9 | -757.1 | -681.8 | -503.8 |
| EBIT 1 | - | -415.2 | -544.5 | -457.4 | -819.8 | -773 | -499 |
| Operating Margin | - | -376.55% | -544.15% | -129.18% | -715.32% | -134.86% | -40.43% |
| Earnings before Tax (EBT) 1 | -818.8 | -3,893 | -303.6 | -356.2 | -790.7 | -752.8 | -482.2 |
| Net income 1 | -818.6 | -3,887 | -308.1 | -359.4 | -792.3 | -702.7 | -473.3 |
| Net margin | - | -3,525.3% | -307.92% | -101.49% | -691.34% | -122.6% | -38.35% |
| EPS 2 | - | -24.17 | -1.180 | -1.370 | -2.932 | -2.529 | -1.693 |
| Free Cash Flow 1 | - | -386.4 | -680.8 | - | -980.5 | -831 | -657.1 |
| FCF margin | - | -350.44% | -680.33% | - | -855.62% | -144.98% | -53.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 25/06/21 | 29/03/22 | 17/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 3,485 | 482 | - | 1,031 | 946 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -386 | -681 | - | -981 | -831 | -657 |
| ROE (net income / shareholders' equity) | - | -22.7% | -8.81% | - | -34.5% | -48% | -45.5% |
| ROA (Net income/ Total Assets) | - | -13% | -7.83% | - | -24.5% | -26.7% | -16.4% |
| Assets 1 | - | 29,902 | 3,933 | - | 3,234 | 2,634 | 2,881 |
| Book Value Per Share 2 | - | 13.10 | 12.00 | - | 8.030 | 5.320 | 3.740 |
| Cash Flow per Share 2 | - | -1.330 | -1.540 | - | -3.270 | -2.650 | -1.020 |
| Capex 1 | - | 172 | 279 | - | 205 | 101 | 99.1 |
| Capex / Sales | - | 155.79% | 278.65% | - | 179.11% | 17.61% | 8.03% |
| Announcement Date | 25/06/21 | 29/03/22 | 17/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.31
CNY
Average target price
54.48
CNY
Spread / Average Target
+68.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.77% | 1.23B | |
| -2.73% | 103B | |
| +1.61% | 95.28B | |
| +1.92% | 22.15B | |
| -15.47% | 21.02B | |
| -8.42% | 18.15B | |
| -41.01% | 16.73B | |
| -13.49% | 16.05B | |
| +3.73% | 13.68B | |
| +35.01% | 12.17B |
- Stock Market
- Equities
- 2162 Stock
- Financials Keymed Biosciences Inc.
